President Donald Trump announced all 50 states will adopt his “GENEROUS” Medicaid drug pricing model, aiming to lower prescription costs by aligning U.S. prices with international benchmarks. The White House claims the program could save $64.3 billion over a decade, but critics question transparency and actual impact.
The Trump administration’s Medicaid drug pricing initiative, dubbed the “GENEROUS” model, has reached a pivotal phase as all 50 states officially commit to participating. Launched through a series of most-favored-nation (MFN) deals, the program seeks to cap Medicaid drug costs by mirroring prices paid in other developed nations. However, the extent of savings and the program’s operational details remain contested, with experts and reporters highlighting gaps in transparency and implementation.
A Blueprint for Lower Costs, But Uncertain Outcomes
The GENEROUS model, short for GENErating cost Reductions fOr U.S. Medicaid,
operates by using international price benchmarks to negotiate supplemental rebates with pharmaceutical manufacturers. Under this framework, the Centers for Medicare & Medicaid Services (CMS) calculates an MFN price based on data from eight countries, including the UK, France, and Japan, and then negotiates rebates to align Medicaid’s net price with that benchmark. The White House claims this approach will reduce federal and state Medicaid spending, with a Council of Economic Advisers (CEA) estimate projecting $64.3 billion in savings over 10 years.
However, the program’s success hinges on participation from both manufacturers and states. While the White House states that 26 pharmaceutical companies—covering 89% of the branded drug market—have signed MFN agreements, details about which drugs will be discounted remain opaque. Pfizer, the first company to announce an agreement in September 2025, pledged to offer all its medications to Medicaid at MFN prices, but other firms have not confirmed similar commitments.
Transparency Gaps and Expert Skepticism
Critics argue the lack of transparency surrounding the MFN deals undermines confidence in the program’s efficacy. The Trump administration has not released the actual agreements with pharmaceutical companies, leaving questions about whether manufacturers are required to discount all their drugs or only select ones.
Moreover, Medicaid net spending on prescription drugs grew by 46% between 2019 and 2024, costing taxpayers $46 billion dollars that year, according to the nonpartisan health policy research group KFF. These existing discounts raise doubts about how much additional savings the GENEROUS model could deliver, particularly for drugs already receiving large rebates.
Political Promises vs. Practical Challenges
Trump has framed the MFN deals as a major victory, claiming they have lowered U.S. drug prices to the lowest prescription drug prices anywhere in the world.
During a September 2025 press event, he asserted, And that alone should get us a big victory in our midterms that are coming up.
The administration’s messaging emphasizes the program’s potential to address rising healthcare costs, a key concern for voters ahead of the midterm elections.
Yet, practical challenges persist. The pilot program relies on voluntary participation, by both drug companies and individual states, which means the number of drugs that will be discounted, and the number of patients who will have access to those prices, could be lower than what Trump originally promised. Additionally, the administration’s refusal to disclose deal details complicates efforts to assess the program’s long-term viability.
Unanswered Questions and the Road Ahead
As the GENEROUS model moves forward, several critical questions remain. How will the program’s savings be distributed between federal and state governments? Will the MFN pricing structure withstand legal or political challenges? And, perhaps most importantly, will patients see meaningful reductions in out-of-pocket costs, or will the savings accrue primarily to taxpayers and states?
The Trump administration has not provided a detailed timeline for full implementation, though it has emphasized that the program is already delivering benefits. Since the launch of TrumpRx.gov in February 2026, patients have saved over $700 million on medications, including discounts on obesity and infertility treatments. However, these savings are limited to specific drugs and may not reflect the broader impact of the MFN model.